Biophan Technologies, Inc., a developer of next-generation medical technology, announced today that the Full Senate Appropriations Committee has approved $400,000 in the Fiscal Year 2007 Energy and Water Appropriations Bill for research on the MYO-VAD cardiac assist device at the Rochester Heart Institute at Rochester General Hospital.
Biophan
Simplifying Global Compliance
Recommended Products
GMP Inspection Preparation Checklist: A Tool for Internal Auditing
This management report includes more than 650 items organized in three sections covering all aspects of quality manufacturing.
Biological Risk Evaluation and Management for Medical Devices
Report shows how the FDA incorporates the two ISO standards in its medical device development policy, how the EU version of the two standards differs in significant ways and how the EU Medical Device Regulation may require further changes in the European standards.
Editor's Picks
NHS England Picks Up Glucose Monitors for Type 1 Diabetes Patients
The devices are now available on prescription for all patients that qualify through NHS’ clinical guidelines.
FDA Expands Approval of Bristol-Myers Squibb’s Empliciti
EPd is the first triplet combination approved based on a randomized clinical trial using pomalidomide and dexamethasone as comparators.
FDAnews Device Daily Bulletin
BIOPHAN ANNOUNCES KEY SENATE APPROVAL OF $400,000 FOR THE MYO-VAD CARDIAC ASSIST DEVICE
July 13, 2006
